News

The publication from Dr. Jessica Chao and Dr. Keith B. Wilson discusses how the COIVD-19 pandemic created additional barriers for people with disabilities already experiencing disparities in medical care.

More than 1,500 people completed brief surveys designed to understand how Kentuckians are responding to the pandemic, with new findings revealing changes in COVID-19 prevention behaviors and attitudes about vaccination.

The UK vaccination clinic has marked a monumental milestone in the fight against the virus — administering 180,000+ COVID-19 vaccines to citizens across the Commonwealth, including front-line health care workers, first responders, teachers, school personnel and people over age 70. Members of the entire UK community have joined forces to help the community meet this unprecedented challenge.

A study from the College of Social Work Self-Care Lab revealed that a majority of participants engaged in moderate levels of self-care before the pandemic, but self-care routines significantly decreased during COVID-19. Self-care for journalists may be impacted by finances, physical health and mental health.

As part of the partnership, Summit will manufacture a multidose nasal spray presentation of AdCOVID, Altimmune’s intranasal COVID-19 vaccine candidate. AdCOVID is currently being evaluated in a phase 1 clinical trial of healthy adult volunteers between the ages of 18 and 55.

The report details the findings of surveys taken by more than 900 healthcare providers, school leaders, community health workers and their clients, and community members in Kentucky during the summer and fall of 2020.

UKNow sat down with University of Kentucky College of Public Health Dean Donna Arnett and Marc Kiviniemi, chair of the Department of Health, Behavior & Society in the College of Public Health, to get some answers on how COVID-19 will affect us moving forward.

“It is too early to tell if 2020 youth suicide death rates are up — this data takes more than a year to compile. But we’re hearing suicide deaths seem to be down, even if attempts and help-seeking are way up,” Julie Cerel said.

On this episode of "Behind the Blue," Dutch talks about the new vaccines being used to combat the coronavirus, the genetic variations of the virus that are appearing in different parts of the world, her outlook for when we may emerge from the pandemic, and more.

The Phase 3 ENSEMBLE 2 study is a randomized, double-blind, placebo-controlled clinical trial in up to 30,000 adults 18 years old and older. The trial will include people both with and without comorbidities associated with an increased risk for severe COVID-19.